| NCT07179055 | An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | RECRUITING | PHASE2 | 2025-10 | 2026-09 | 2026-09 |
| NCT07090161 | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | NOT_YET_RECRUITING | PHASE2 | 2025-07-28 | 2026-11 | 2026-10 |
| NCT06961968 | Randomized Withdrawal Study in Patients With Schizophrenia | RECRUITING | PHASE3 | 2025-05-14 | 2027-11 | 2027-11 |
| NCT07065773 | Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis | RECRUITING | PHASE2 | 2025-05-05 | 2026-05 | 2026-03 |
| NCT06953869 | Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia | RECRUITING | PHASE3 | 2025-04-21 | 2028-01 | 2027-11 |
| NCT06830044 | Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | RECRUITING | PHASE3 | 2025-03-03 | 2028-03 | 2028-03 |
| NCT06804603 | A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use | RECRUITING | PHASE2 | 2025-02-25 | 2025-09-01 | 2025-09-01 |
| NCT06701396 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant | RECRUITING | PHASE3 | 2024-10-08 | 2025-06-30 | 2025-06-30 |
| NCT06494397 | Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions | COMPLETED | PHASE1 | 2024-07-11 | 2024-10-24 | 2024-10-24 |
| NCT06296966 | A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye | RECRUITING | PHASE2 | 2024-02-29 | 2024-07 | 2024-07 |
| NCT06836557 | Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis | RECRUITING | PHASE3 | 2024-01-09 | 2025-12 | 2025-12 |
| NCT05903924 | Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness | COMPLETED | PHASE3 | 2023-09-09 | 2024-04-24 | 2024-04-06 |
| NCT05648591 | Safety and Tolerability of Open-Labeled Iloperidone in Adolescents | RECRUITING | PHASE4 | 2023-05-24 | 2026-11-30 | 2026-03-31 |
| NCT06138613 | Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness | RECRUITING | PHASE3 | 2023-02-27 | 2025-04-30 | 2025-04-30 |
| NCT06803290 | Food Effect Study of VHX-896 in Healthy Volunteers | COMPLETED | PHASE1 | 2022-06-21 | 2022-12-27 | 2022-12-27 |
| NCT05344365 | A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis | WITHDRAWN | PHASE2 | 2022-06 | 2023-11 | 2023-11 |
| NCT05572281 | Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers | COMPLETED | PHASE1 | 2022-05-18 | 2022-06-15 | 2022-06-15 |
| NCT05366855 | Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis | TERMINATED | PHASE3 | 2022-04-21 | 2024-07-17 | 2024-02-08 |
| NCT05352893 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | COMPLETED | PHASE3 | 2022-04-14 | 2023-08-17 | 2023-08-17 |
| NCT04327661 | Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness | COMPLETED | PHASE3 | 2021-11-15 | 2023-04-12 | 2023-04-01 |
| NCT05361707 | Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances | RECRUITING | PHASE3 | 2021-07-28 | 2025-07 | 2025-07 |
| NCT04856930 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa | COMPLETED | PHASE2 | 2021-07-07 | 2022-12-14 | 2022-07-15 |
| NCT04969211 | Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers | COMPLETED | PHASE1 | 2021-06-30 | 2021-10-13 | 2021-10-13 |
| NCT04856917 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris | COMPLETED | PHASE2 | 2021-05-15 | 2022-03-29 | 2022-02-01 |
| NCT04697069 | A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash | TERMINATED | PHASE2 | 2021-05-04 | 2021-12-13 | 2021-12-13 |
| NCT04819776 | Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder | COMPLETED | PHASE3 | 2021-03-22 | 2023-08-16 | 2022-09-07 |
| NCT04800237 | Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety | COMPLETED | PHASE2 | 2021-02-23 | 2022-08-02 | 2022-08-02 |
| NCT04849559 | Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers | COMPLETED | PHASE1, PHASE2 | 2021-02-01 | 2021-09-24 | 2021-09-24 |
| NCT04697056 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis | TERMINATED | PHASE2 | 2021-01-25 | 2021-11-19 | 2021-11-19 |
| NCT04712734 | A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia | COMPLETED | PHASE1 | 2021-01-13 | 2022-08-30 | 2022-08-30 |
| NCT04652882 | Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) | RECRUITING | PHASE3 | 2020-12-09 | 2025-12 | 2025-12 |
| NCT04622345 | Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies | COMPLETED | PHASE2 | 2020-11-21 | 2021-06-28 | 2021-05-22 |
| NCT04326426 | ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection | ENROLLING_BY_INVITATION | PHASE3 | 2020-04-13 | 2020-08-31 | 2020-08-01 |
| NCT04140695 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2) | TERMINATED | PHASE3 | 2019-10-21 | 2020-10-14 | 2020-10-14 |
| NCT04127058 | Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia | COMPLETED | PHASE1 | 2019-10-07 | 2019-11-27 | 2019-11-27 |
| NCT04028492 | Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis | COMPLETED | PHASE3 | 2019-08-20 | 2025-02-21 | 2025-02-21 |
| NCT03633396 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis | COMPLETED | PHASE2 | 2019-05-20 | 2021-04-23 | 2021-04-23 |
| NCT03619902 | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis | COMPLETED | PHASE2 | 2019-01-30 | 2021-01-20 | 2021-01-20 |
| NCT03772340 | Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness | COMPLETED | PHASE2 | 2018-12-20 | 2019-06-27 | 2019-06-06 |
| NCT03838926 | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies | RECRUITING | PHASE1 | 2018-09-27 | 2025-12 | 2025-12 |
| NCT06323655 | Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects | COMPLETED | PHASE1 | 2018-07-19 | 2018-08-28 | 2018-08-28 |
| NCT03568331 | Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) | COMPLETED | PHASE3 | 2018-07-09 | 2019-12-27 | 2019-12-27 |
| NCT03373201 | Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia | COMPLETED | PHASE3 | 2017-10-16 | 2018-03-05 | 2018-03-05 |
| NCT02970968 | Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis | COMPLETED | PHASE2 | 2016-11 | 2018-12 | 2018-11 |
| NCT02776215 | Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | COMPLETED | PHASE1 | 2016-10-04 | 2017-12-20 | 2017-12-20 |
| NCT03291041 | A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder | COMPLETED | PHASE2 | 2016-07 | 2017-11 | 2017-11 |
| NCT02651714 | Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis | COMPLETED | PHASE2 | 2016-01-19 | 2017-08-04 | 2017-08-04 |
| NCT02621385 | Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects | COMPLETED | PHASE1 | 2015-11 | | 2016-02 |
| NCT02231008 | Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS | COMPLETED | PHASE2, PHASE3 | 2015-09 | 2022-01 | 2018-11-19 |
| NCT02130999 | Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZâ„¢) | COMPLETED | PHASE4 | 2014-05 | 2014-05 | 2014-05 |
| NCT02004041 | Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis | COMPLETED | PHASE2 | 2013-12-10 | 2015-02-19 | 2015-02-19 |
| NCT01919944 | Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P | COMPLETED | PHASE1 | 2013-08 | 2013-11 | 2013-11 |
| NCT01637636 | Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin. | COMPLETED | PHASE1 | 2012-06 | 2012-08 | 2012-08 |
| NCT01578057 | Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol | COMPLETED | PHASE1 | 2012-04 | 2012-06 | 2012-06 |
| NCT01540500 | Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine | COMPLETED | PHASE1 | 2012-02 | 2012-03 | 2012-03 |
| NCT01526746 | Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function | COMPLETED | PHASE1 | 2012-02 | 2012-06 | 2012-06 |
| NCT01477619 | Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects | COMPLETED | PHASE1 | 2011-11 | 2012-01 | 2012-01 |
| NCT01495169 | Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients | COMPLETED | PHASE1 | 2011-10 | 2015-02 | 2015-02 |
| NCT01429116 | Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception | COMPLETED | PHASE3 | 2011-10 | 2015-01 | 2015-01 |
| NCT01428661 | Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder | COMPLETED | PHASE2, PHASE3 | 2011-09 | 2013-05 | 2013-01 |
| NCT01430754 | Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder | COMPLETED | PHASE3 | 2011-09 | 2012-12 | 2012-12 |
| NCT01402076 | A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects | COMPLETED | PHASE1 | 2011-08 | 2011-08 | 2011-08 |
| NCT01291511 | Relapse Prevention Study in Patients With Schizophrenia | COMPLETED | PHASE3 | 2011-02 | 2015-03 | 2014-03 |
| NCT01271387 | Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment | COMPLETED | PHASE1 | 2011-01 | 2011-08 | 2011-08 |
| NCT01218789 | Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception | ACTIVE_NOT_RECRUITING | PHASE3 | 2010-10-28 | 2024-12-05 | 2024-12-05 |
| NCT01163032 | Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder | COMPLETED | PHASE3 | 2010-08 | 2012-11 | 2012-11 |
| NCT00548340 | VEC-162 Study in Adult Patients With Primary Insomnia | COMPLETED | PHASE3 | 2007-11 | 2008-06 | 2008-02 |
| NCT00291187 | VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia | COMPLETED | PHASE3 | 2006-02 | 2006-08 | 2006-08 |
| NCT00254202 | Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia | COMPLETED | PHASE3 | 2005-11-18 | 2007-03-21 | 2006-09-26 |
| NCT00490945 | Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers | COMPLETED | PHASE2 | 2004-07 | 2005-03 | 2005-03 |
| NCT00467441 | VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness | COMPLETED | PHASE2 | | | |